| Preferred drug | Lansoprazole | Simvastatin | Ramipril | Candesartan | Venlafaxine | Citalopram | ER tolterodine | |
| Total no. of single-agent items | 4 571 751 | 1 313 389 | 4 719 996 | 557 622 | 1 155 600 | 1 650 520 | 577 540 | |
| % within class | 24.14 % | 6.59 % | 53.41 % | 10.78 % | 70.99 % | 19.77 % | 25.79 % | |
| Rank within class pre-PDI | 2/5 | 4/5 | 1/10 | 5/8 | 1/2 | 2/6 | 1/9 | |
| Rank within class post-PDI | 2/5 | 4/5 | 1/10 | 5/8 | 1/2 | 3/6 | 3/9 | |
| Absolute change in proportion of preferred drug items: first 3 months post-PDI versus previous 3 months | ↑ +0.98% (P<0.001) | ↑ +0.30% (P<0.001) | ↑ 0.53% (P<0.001) | ↓ −0.01% (P=0.99) | ↑ 0.30% (P=0.08) | ↓ −0.09% (P=0.37) | ↓ −0.98% (P<0.001) |
ARB, angiotensin-II receptor blocker; ER, extended release; PDI, Preferred Drugs Initiative; PPI, proton pump inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.